About Sanofi
Industry:
Pharmaceuticals
Founded:
2004
Founders:
Merger of Sanofi-Synthélabo and Aventis
Status:
Public (NASDAQ: SNY)
Funding & Growth
Total Raised:
N/A
Valuation:
$130B+ market cap
Stage:
Public
Key Investors:
Public markets
✓ Pros
- • Strong immunology portfolio (Dupixent)
- • Cambridge, MA hub
- • Global vaccine leader
- • Good work-life balance
- • Diverse therapeutic areas
✗ Cons
- • French headquarters (timezone)
- • Corporate restructuring
- • Large company processes
- • Some legacy systems